Clinical Development Crystal Ball: What To Watch In 2026

The clinical development landscape is rapidly evolving, driven by the convergence of scientific innovation, complex operational demands, and intensifying regulatory pressures. To succeed in 2026, organizations must adopt measurement strategies and scalable digital infrastructures that balance scientific rigor with commercial efficiency. This outlook examines critical trends, including the transition of AI from pilot projects into routine clinical operations, where its value lies in enhancing data quality and decision-making, rather than making broad transformation promises. It also examines the expansion of remote assessments to improve trial inclusivity and reduce screen failure costs, particularly in neuroscience. Furthermore, the content addresses new measurement challenges in rare disease development, the booming GLP-1 pipeline, and the complexities of functional unblinding in psychedelic trials.

By understanding these shifts, sponsors and CROs can better prepare to turn promising pipelines into approved therapies.